Top Mesothelioma Centers in Tennessee

Several internationally recognized cancer centers provide mesothelioma treatment in Tennessee, including the National Cancer Institute-recognized Vanderbilt-Ingram Cancer Center in Nashville. This NCI-Designated Comprehensive Cancer Center provides exceptional patient care, stays at the cutting edge of cancer research and is home to some of the best pleural mesothelioma doctors in Tennessee.

Other cancer centers for mesothelioma patients in the state include the Sarah Cannon Research Institute in Nashville, the West Cancer Center & Research Institute in Memphis and Tennessee Oncology centers throughout Tennessee. The West Cancer Center was the first in the country to offer Tumor Treating Fields therapy for pleural mesothelioma.

Locations of Tennessee’s Top Cancer Centers

Patients can find the top Tennessee mesothelioma doctors and cancer centers in Nashville, Memphis, Chattanooga, Paris, Johnson City and other areas. The state’s only NCI-Designated Cancer Center for adult patients is the Vanderbilt-Ingram Cancer Center in Nashville. Dozens of Tennessee Oncology and West Cancer Center locations provide medical oncology, radiation oncology and supportive care to patients throughout the state.

All Centers (3)

Top Doctors in Tennessee

The best mesothelioma doctors in Tennessee are thoracic and abdominal cancer experts with decades of experience in medical oncology, radiation oncology or surgical cancer treatments. Dr. Eric S. Lambright at the Vanderbilt-Ingram Cancer Center is an award-winning mesothelioma doctor with decades of expertise in thoracic oncology. Dr. Lambright specializes in complex or malignant pulmonary cancers.

Mesothelioma specialists often lead clinical trials and multidisciplinary care teams at cancer centers in Tennessee. Dr. Evan Osmundson is the Medical Director at Vanderbilt-Ingram and a vital part of the Department of Radiation Oncology. Dr. Osmundson provides targeted cancer treatments such as Intensity-Modulated Radiation Therapy and leads immunotherapy clinical trials in Tennessee.

Dr. Matthew Ballo

Matthew Ballo

Pleural Specialist | Radiation Oncology

Expertise:
Tumor Treating Fields Research
West Cancer Center & Research Institute • Memphis, Tennessee
View Profile
Expertise:
Tumor Treating Fields Research
West Cancer Center & Research Institute
Memphis, Tennessee
View Profile

Dr. Matthew Ballo is the director of Radiation Oncology at the West Cancer Center & Research Institute in Memphis, helping pioneer the use of Tumor Treating Fields for malignant pleural mesothelioma.

Read Bio
Dr. Eric S. Lambright

Eric S. Lambright

Pleural Specialist | Thoracic Surgery

Expertise:
Chest Wall Resection Immunotherapy
Vanderbilt-Ingram Cancer Center • Franklin, Tennessee
View Profile
Expertise:
Chest Wall Resection Immunotherapy
Vanderbilt-Ingram Cancer Center
Franklin, Tennessee
View Profile

Dr. Eric S. Lambright is chief of thoracic surgery at Nashville Veterans Affairs Medical Center. He is actively involved in groundbreaking research for thoracic malignancies such as mesothelioma and lung cancer.

Read Bio
Dr. Evan Osmundson

Evan Osmundson

Pleural Specialist | Radiation Oncology

Expertise:
Intensity Modulated Radiotherapy Intraoperative Radiation Therapy
Vanderbilt-Ingram Cancer Center • Nashville, Tennessee
View Profile
Expertise:
Intensity Modulated Radiotherapy Intraoperative Radiation Therapy
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
View Profile

Dr. Evan Osmundson is a radiation oncologist in Tennessee at Vanderbilt-Ingram Cancer Center with expertise in treating liver, lung and pleural mesothelioma cancers.

Read Bio
Dr. Sally J. York

Sally J. York

Pleural Specialist | Thoracic Oncology

Expertise:
Hematologic Oncology Thoracic Cancer
Vanderbilt-Ingram Cancer Center • Nashville, Tennessee
View Profile
Expertise:
Hematologic Oncology Thoracic Cancer
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
View Profile

Dr. Sally York is a medical oncologist and associate professor who treats patients with lung cancer and pleural mesothelioma at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Read Bio
Find a Specialist Near You

Begin your search for a doctor in your area.

Searching…

Get started by selecting location, type, specialty or language.

Clinical Trials and Cancer Research in Tennessee

In addition to providing comprehensive medical care, many of Tennessee’s mesothelioma cancer centers focus on clinical research as well, such as the Sarah Cannon Research Institute in Nashville. Mesothelioma clinical trials in Tennessee can lead to innovative therapies, such as new chemotherapy medicines or immunotherapy treatments that help the body target cancer cells more effectively. 

Speak with your mesothelioma doctor or our knowledgeable Patient Advocates for help finding and enrolling in clinical trials in your area. Enrolling in a clinical trial may give you access to emerging mesothelioma treatments.

NCT06566079

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic mesothelioma or other Advanced solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection expansion part (Part 2).

Locations

  • Colorado (1)

    • Sarah Cannon Research Institute at HealthONE — Denver

  • Illinois (1)

    • The University of Chicago Medical Center – Duchossois Center for Advanced Medicine — Chicago

  • Ohio (1)

    • University Hospitals Cleveland Medical Center — Cleveland

  • Pennsylvania (1)

    • University of Pennsylvania – Abramson Cancer Center — Philadelphia

  • Tennessee (1)

    • SCRI Oncology Partners — Nashville

  • Texas (1)

    • NEXT Oncology – Austin — Austin

NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Locations

  • California (1)

    • Providence Medical Foundation — Santa Rosa

  • District of Columbia (1)

    • Johns Hopkins Sibley Memorial Hospital — Washington D.C.

  • Florida (3)

    • BRCR Global-Coral Springs — Coral Springs
    • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando
    • Moffitt Cancer Center — Tampa

  • Nebraska (1)

    • Nebraska Cancer Specialists — Omaha

  • New Jersey (1)

    • START Astera, LLC — East Brunswick

  • New York (1)

    • Columbia University Irving Medical Center — New York

  • Pennsylvania (1)

    • Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University — Philadelphia

  • Tennessee (1)

    • Sarah Cannon Research Institute — Nashville

  • Texas (4)

    • START Dallas Fort Worth — Fort Worth
    • MD Anderson — Houston
    • NEXT Oncology Houston — Houston
    • NEXT Oncology Dallas — Irving

  • Utah (1)

    • START Mountain Region, LLC — West Valley City

  • Virginia (1)

    • NEXT Oncology Virginia — Fairfax

  • Washington (1)

    • Swedish Cancer Institute — Seattle

NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Locations

  • Arizona (1)

    • Mayo Clinic — Phoenix

  • Colorado (1)

    • Rocky Mountain Cancer Centers, LLP – Oncology — Lone Tree

  • Florida (2)

    • Mayo Clinic — Jacksonville
    • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando

  • Massachusetts (1)

    • Dana-Farber Cancer Institute — Brookline

  • Michigan (2)

    • The Cancer & Hematology Centers — Grand Rapids
    • Cancer and Hematology Centers of Western Michigan — Norton Shores

  • Minnesota (1)

    • Mayo Clinic — Rochester

  • New Jersey (1)

    • Rutgers Cancer Institute of New Jersey — New Brunswick

  • New York (4)

    • Perlmutter Cancer Center at NYU Langone Hospital Long Island — Mineola
    • David H Koch, Memorial Sloan Kettering Cancer Center — New York
    • New york cancer and blood specialists – Oncology — Port Jefferson Station
    • New york cancer and blood specialists – Oncology — Port Jefferson Station

  • North Carolina (2)

    • University of North Carolina – Gastroenterology and Hepatology — Chapel Hill
    • University of North Carolina — Chapel Hill

  • Tennessee (1)

    • Vanderbilt – Ingram Cancer Center — Nashville

  • Texas (5)

    • Ut Southwestern — Dallas
    • Texas Oncology – DFW — Fort Worth
    • MDACC — Houston
    • South Texas Accelerated Research Therapeutics — San Antonio
    • Texas Oncology, P.A. – Oncology — Tyler

  • Virginia (1)

    • Virginia Cancer Specialists, PC — Fairfax

NCT06756035

CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.

Locations

  • Colorado (1)

    • Context Investigational Site — Denver

  • Illinois (1)

    • Context Investigational Site — Chicago

  • Michigan (1)

    • Context Investigational Site — Grand Rapids

  • New Jersey (1)

    • Context Investigational Site — Hackensack

  • Pennsylvania (2)

    • University of Pennsylvania — Philadelphia
    • Context Investigational Site — Philadelphia

  • Tennessee (1)

    • Context Investigational Site — Nashville

  • Texas (2)

    • Context Investigational Site — San Antonio
    • Context Investigational Site — San Antonio

NCT05732831

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Locations

  • California (1)

    • Stanford University — Palo Alto

  • Colorado (1)

    • Grand Valley Oncology — Grand Junction

  • Florida (1)

    • Sylvester Comprehensive Cancer Center — Miami

  • Illinois (3)

    • University Chicago Medicine — Chicago
    • Carle Cancer Center — Urbana
    • Midwestern Regional Medical Center, City of Hope Chicago — Zion

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (1)

    • Henry Ford Cancer Center — Detroit

  • New York (1)

    • New York University Langone Health — New York

  • Tennessee (1)

    • Sarah Cannon Tennessee Oncology — Nashville

  • Texas (1)

    • The University of Texas MD Anderson Cancer Center — Houston

  • Utah (1)

    • Huntsman Cancer Institute, University of Utah — Salt Lake City

  • Virginia (1)

    • Next Oncology Virginia — Fairfax

NCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.

Locations

  • Arizona (2)

    • Banner Health — Gilbert
    • Mayo Clinic Hospital — Phoenix

  • California (3)

    • University of California San Diego — La Jolla
    • Stanford University — Palo Alto
    • UCLA Medical Center — Santa Monica

  • Florida (2)

    • Mayo Clinic Jacksonville — Jacksonville
    • Moffitt Cancer Center — Tampa

  • Minnesota (1)

    • Mayo Clinic Rochester — Rochester

  • Missouri (1)

    • Washington University — St Louis

  • New York (1)

    • NYU Langone Medical Center — New York

  • Ohio (1)

    • The Ohio State University Comprehensive Cancer Center — Columbus

  • Tennessee (1)

    • Vanderbilt University Medical Center — Nashville

  • Washington (1)

    • Fred Hutchinson Cancer Center — Seattle

NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Locations

  • Arizona (2)

    • USOR HonorHealth — Phoenix
    • USOR Arizona Oncology Associates — Tucson

  • California (4)

    • University of California Los Angeles Medical Center — Los Angeles
    • University of California, San Diego; Moores Cancer Center — San Diego
    • USOR Sansum Clinic — Santa Barbara
    • Providence Medical Foundation — Santa Rosa

  • Florida (3)

    • USOR Florida Cancer Specialists South — Fort Myers
    • USOR Florida Cancer Specialists North — St. Petersburg
    • USOR Florida Cancer Specialists East — West Palm Beach

  • Georgia (1)

    • Augusta University Georgia Cancer Center — Augusta

  • Kansas (1)

    • University of Kansas Medical Center (KUMC) — Westwood

  • Maryland (1)

    • USOR Maryland Oncology Hematology — Rockville

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (2)

    • Karmanos Cancer Institute — Detroit
    • START Midwest — Grand Rapids

  • Minnesota (1)

    • USOR Minnesota Oncology Hematology — Maplewood

  • New Jersey (1)

    • MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden

  • Ohio (1)

    • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus

  • Oklahoma (1)

    • University of Oklahoma – Health Sciences Center — Oklahoma City

  • Oregon (2)

    • USOR Oncology Associates of Oregon, P.C. — Eugene
    • Compass Oncology – Rose Quarter — Portland

  • Pennsylvania (2)

    • USOR Alliance Cancer Specialist — Doylestown
    • Allegheny Health Network — Pittsburgh

  • Rhode Island (1)

    • Women and Infants Hospital of Rhode Island — Providence

  • Tennessee (2)

    • Sarah Cannon Research Institute at Tennessee Oncology — Nashville
    • Tennessee Oncology — Nashville

  • Texas (6)

    • USOR Texas Oncology — Abilene
    • Texas Oncology – Central / South Texas — Austin
    • Mary Crowley Cancer Research — Dallas
    • USOR Texas Oncology — Fort Worth
    • Texas Oncology – Northeast TX — Tyler
    • USOR Texas Oncology Gulf Coast — Woodland

  • Utah (1)

    • START Mountain Region — West Valley City

  • Virginia (2)

    • USOR Virginia Cancer Specialists — Fairfax
    • USOR Virginia Oncology Associates — Norfolk

  • Washington (1)

    • Swedish Cancer Institute — Seattle

NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose

Locations

  • Arizona (1)

    • Banner Health — Gilbert

  • California (3)

    • UCSD Moores Cancer Center — La Jolla
    • UCLA Medical Center — Los Angeles
    • Stanford University — Stanford

  • Florida (2)

    • Mayo Clinic — Jacksonville
    • Moffitt Cancer Center — Tampa

  • Minnesota (1)

    • Mayo Clinic Rochester — Rochester

  • Missouri (1)

    • Washington University — St Louis

  • New York (1)

    • NYU Langone Medical Center — New York

  • Ohio (1)

    • The Ohio State University Comprehensive Cancer Center — Columbus

  • Tennessee (1)

    • Vanderbilt University Medical Center — Nashville

  • Washington (1)

    • Fred Hutchinson Cancer Center — Seattle

Financial Support for Treatment in Tennessee

Financial aid programs in Tennessee can help cancer patients cover essential household expenses during treatment or after surgery, such as rent, insurance premiums or food. Nonprofits like the Bedford Cancer Foundation can alleviate some of the stress on mesothelioma patients, caregivers and family members.

Organizations Offering Financial Aid

  • Bedford Cancer Foundation: Mesothelioma patients in Bedford County can qualify for direct financial aid to help with household expenses during treatment. Bedford Cancer Foundation doesn’t cover medical bills, but the grants can help with medical insurance premiums, mortgage payments, car payments and similar costs. The Foundation has provided more than $850,000 to Bedford County cancer patients since 2009.
  • Multi-County Cancer Support Network: Families facing economic hardships because of mesothelioma treatment costs can benefit from short-term financial aid from this southern Tennessee nonprofit. The MCCSN can cover travel expenses for treatment, utility bills and food. Patients must live in Bedford, Franklin, Grundy, Moore, Warren or surrounding counties. 
  • Sherry’s Hope: Based in Lebanon, Sherry’s Hope is a faith-based nonprofit that provides financial aid and spiritual support to cancer patients in and around Wilson County. The organization can help with medical bills, prescription costs and non-medical expenses like groceries, rent and utility bills. To qualify, patients must be in active treatment or hospice care.

Our Veterans Department is proud to support Tennessee veterans who have mesothelioma. We can help local veterans navigate financial aid programs and apply for VA benefits, such as disability compensation. All mesothelioma patients can get 1-on-1 assistance from our experienced Patient Advocates to find county, state and national aid programs.

Cancer Resources in Tennessee

Organizations like F.A.I.T.H. Cancer Care Foundation provide virtual cancer support groups and educational resources throughout Tennessee. Mesothelioma patients who live near Nashville, Knoxville and Memphis can also access in-person wellness services, including physical therapy, nutrition assistance and mental health support from nonprofits like the West Cancer Foundation.

Tennessee Cancer Nonprofits and Support Groups

  • Cancer Support Community East Tennessee: Mesothelioma patients in Knox County can find a wide range of support programs at Cancer Support Community’s Knoxville resource center, from cooking and art classes to gentle exercise activities and stress management programs. Weekly support groups provide comfort and strength for patients, caregivers and bereaved families.
  • F.A.I.T.H. Cancer Care Foundation: Located in Clarksville, F.A.I.T.H. offers educational resources, creative workshops, support groups and nutritional programs for cancer patients throughout the state. Patients and their caregivers in Davidson and Williamson Counties can enjoy free meal delivery service during treatment.
  • Gilda’s Club Middle Tennessee: Named after comedian Gilda Radner, Gilda’s Club provides social, emotional and practical support to cancer patients and their families. In addition to offering free wigs and cancer accessories, the nonprofit helps connect visitors with local aid programs.
  • Heimerdinger Foundation: Since 2013, this Nashville nonprofit has supported local families with nutritious, freshly prepared meals delivered directly to the patient’s home every Tuesday. Heimerdinger Foundation’s meal program has helped more than 4,000 caregivers and cancer patients. Mesothelioma patients can apply for 12 weeks of free meals.
  • Vanderbilt Cancer Support Services: The Vanderbilt-Ingram Cancer Center goes beyond world-class mesothelioma treatment. This NCI-Designated cancer center in Tennessee also provides comprehensive family and patient support services, including transportation and lodging assistance, financial counseling and psychological care. The center’s Integrative Oncology program focuses on helping cancer survivors improve their quality of life, mental health and physical wellness.
  • Waves of Grace: This Brentwood nonprofit helps fund weeklong beach getaways for Tennessee cancer patients and their loved ones. Depending on available donations, Waves of Grace can cover travel costs, meals, venue entertainment, hotel stays and medical equipment rentals.
  • West Cancer Foundation: Based in Memphis, the West Cancer Foundation provides chemotherapy support programs and transportation services to cancer patients in West Tennessee. Mesothelioma patients in the Memphis region can also schedule free counseling sessions with licensed mental health professionals, either in person or virtually.

Tennessee’s 211 helpline makes it easy for families facing a mesothelioma diagnosis to find free local support programs, such as rides or meal services. Regional 211 resource hubs are available in Chattanooga, Jackson, Memphis, Nashville and Knoxville

What Survivors Say About Their Mesothelioma Treatment in Tennessee

Cancer patients who have received mesothelioma treatment in Tennessee have shared their experiences with our Patient Advocate team. Thanks to excellent patient care and support, advanced treatments like heated chemotherapy and cutting-edge clinical trials at NCI-Designated Cancer Centers, Tennessee mesothelioma survivors have been able to enjoy more time with loved ones.

Survivor Experience

“Be your own advocate. The cancer doesn’t respond well to standard treatment, so you have to find someone who goes beyond standard and is interested in experimental drugs. Someone not afraid to try something new.”

– Jim M. , Peritoneal Mesothelioma Survivor
Verified Asbestos.com Survivor